Jupiter Asset Management Ltd. Has $3.95 Million Position in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)

Key Points

• Jupiter Asset Management Ltd. reduced its holdings in Alnylam Pharmaceuticals by 5.3%, owning 14,610 shares worth approximately $3.95 million at the end of the first quarter.
• Several hedge funds increased their stakes in Alnylam, with Capital Research Global Investors raising its position by 32.9%, now owning over 6.9 million shares valued at around $1.64 billion.
• Analyst ratings for Alnylam Pharmaceuticals are predominantly positive, with 23 analysts giving it a "buy" rating and an average target price of $392.13.

Jupiter Asset Management Ltd. lowered its holdings in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Free Report) by 5.3% during the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 14,610 shares of the biopharmaceutical company's stock after selling 825 shares during the quarter. Jupiter Asset Management Ltd.'s holdings in Alnylam Pharmaceuticals were worth $3,945,000 at the end of the most recent quarter.

A number of other hedge funds also recently modified their holdings of ALNY. Capital Research Global Investors raised its position in Alnylam Pharmaceuticals by 32.9% in the 4th quarter. Capital Research Global Investors now owns 6,968,513 shares of the biopharmaceutical company's stock valued at $1,639,767,000 after buying an additional 1,724,610 shares during the last quarter. T. Rowe Price Investment Management Inc. raised its position in Alnylam Pharmaceuticals by 39.7% in the 4th quarter. T. Rowe Price Investment Management Inc. now owns 4,384,449 shares of the biopharmaceutical company's stock valued at $1,031,705,000 after buying an additional 1,245,195 shares during the last quarter. Marshall Wace LLP raised its position in Alnylam Pharmaceuticals by 496.6% in the 4th quarter. Marshall Wace LLP now owns 378,649 shares of the biopharmaceutical company's stock valued at $89,100,000 after buying an additional 315,182 shares during the last quarter. AQR Capital Management LLC raised its position in Alnylam Pharmaceuticals by 60.9% in the 4th quarter. AQR Capital Management LLC now owns 813,356 shares of the biopharmaceutical company's stock valued at $191,391,000 after buying an additional 307,702 shares during the last quarter. Finally, Allspring Global Investments Holdings LLC acquired a new stake in Alnylam Pharmaceuticals in the 1st quarter valued at approximately $69,292,000. Institutional investors and hedge funds own 92.97% of the company's stock.

Wall Street Analyst Weigh In

A number of equities research analysts recently issued reports on ALNY shares. Citigroup lifted their target price on Alnylam Pharmaceuticals from $364.00 to $404.00 and gave the company a "buy" rating in a research report on Friday, July 11th. JPMorgan Chase & Co. lifted their target price on Alnylam Pharmaceuticals from $338.00 to $348.00 and gave the company an "overweight" rating in a research report on Wednesday, July 16th. Piper Sandler lifted their target price on Alnylam Pharmaceuticals from $304.00 to $449.00 and gave the company an "overweight" rating in a research report on Friday. Truist Financial started coverage on Alnylam Pharmaceuticals in a research report on Monday, July 21st. They issued a "buy" rating and a $385.00 target price on the stock. Finally, Scotiabank lifted their target price on Alnylam Pharmaceuticals from $342.00 to $450.00 and gave the company a "sector outperform" rating in a research report on Friday. One equities research analyst has rated the stock with a sell rating, three have issued a hold rating and twenty-three have given a buy rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and an average target price of $392.13.

Alnylam Pharmaceuticals Stock Performance

ALNY opened at $401.80 on Monday. The business has a fifty day simple moving average of $318.24 and a 200 day simple moving average of $279.01. The company has a market capitalization of $52.67 billion, a PE ratio of -162.67 and a beta of 0.25. Alnylam Pharmaceuticals, Inc. has a 1 year low of $205.87 and a 1 year high of $402.43. The company has a debt-to-equity ratio of 8.88, a current ratio of 3.04 and a quick ratio of 2.98.

Alnylam Pharmaceuticals (NASDAQ:ALNY - Get Free Report) last released its quarterly earnings results on Thursday, May 1st. The biopharmaceutical company reported ($0.44) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.37) by ($0.07). The firm had revenue of $594.19 million during the quarter, compared to the consensus estimate of $584.32 million. Alnylam Pharmaceuticals had a negative net margin of 12.96% and a negative return on equity of 444.38%. The business's revenue for the quarter was up 20.2% compared to the same quarter last year. During the same quarter last year, the firm earned ($0.16) earnings per share. Research analysts expect that Alnylam Pharmaceuticals, Inc. will post -1.7 EPS for the current year.

Insider Transactions at Alnylam Pharmaceuticals

In related news, CEO Yvonne Greenstreet sold 19,297 shares of the business's stock in a transaction on Monday, June 2nd. The stock was sold at an average price of $306.00, for a total value of $5,904,882.00. Following the completion of the sale, the chief executive officer directly owned 48,948 shares in the company, valued at $14,978,088. The trade was a 28.28% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. 1.20% of the stock is owned by company insiders.

Alnylam Pharmaceuticals Company Profile

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.